Literature DB >> 29493783

Precious GEMMs: emergence of faithful models for ovarian cancer research.

Sarah Stuckelberger1, Ronny Drapkin1,2.   

Abstract

The development of Genetically Engineered Mouse Models (GEMMs) has catalyzed tremendous progress in cancer research. However, it has been difficult to design adequate mouse models for high-grade serous carcinoma (HGSC), the most common and lethal form of ovarian cancer. The genetic complexity of the disease, as well as the recent appreciation that most HGSCs arise from the fallopian tube (FT) secretory epithelium rather than the ovarian surface epithelium, has stifled the development of robust GEMMs. In a recent issue of this journal, Zhai et al presented an elegant mouse model for ovarian cancer that uses Ovgp1 as an FT-specific promoter to inactivate Brca1, Trp53, Rb1, Nf1, and Pten. The authors showed that loss of these genes in the mouse FT epithelium can mimic the different stages of human HGSC tumorigenesis. Their robust model emphasizes the importance of considering both the cell of origin and tumor genetics in developing accurate model systems. They provide a useful tool for studying mechanisms of disease in vivo and for research into novel methods of prevention, early detection, and treatment of HGSC.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  fallopian tube; genetically engineered mouse models; high-grade serous carcinoma; ovarian cancer

Mesh:

Substances:

Year:  2018        PMID: 29493783     DOI: 10.1002/path.5065

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

Review 1.  Harnessing the predictive power of preclinical models for oncology drug development.

Authors:  Alexander Honkala; Sanjay V Malhotra; Shivaani Kummar; Melissa R Junttila
Journal:  Nat Rev Drug Discov       Date:  2021-10-26       Impact factor: 84.694

2.  The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.

Authors:  Daniele Chaves-Moreira; Marilyn A Mitchell; Cristina Arruza; Priyanka Rawat; Simone Sidoli; Robbin Nameki; Jessica Reddy; Rosario I Corona; Lena K Afeyan; Isaac A Klein; Sisi Ma; Boris Winterhoff; Gottfried E Konecny; Benjamin A Garcia; Donita C Brady; Kate Lawrenson; Patrice J Morin; Ronny Drapkin
Journal:  Sci Signal       Date:  2022-04-05       Impact factor: 9.517

Review 3.  The tubal epigenome - An emerging target for ovarian cancer.

Authors:  Hunter D Reavis; Ronny Drapkin
Journal:  Pharmacol Ther       Date:  2020-03-18       Impact factor: 12.310

Review 4.  Cell Origins of High-Grade Serous Ovarian Cancer.

Authors:  Jaeyeon Kim; Eun Young Park; Olga Kim; Jeanne M Schilder; Donna M Coffey; Chi-Heum Cho; Robert C Bast
Journal:  Cancers (Basel)       Date:  2018-11-12       Impact factor: 6.639

5.  In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.

Authors:  Olga Kim; Eun Young Park; David L Klinkebiel; Svetlana D Pack; Yong-Hyun Shin; Zied Abdullaev; Robert E Emerson; Donna M Coffey; Sun Young Kwon; Chad J Creighton; Sanghoon Kwon; Edmund C Chang; Theodore Chiang; Alexander N Yatsenko; Jeremy Chien; Dong-Joo Cheon; Yang Yang-Hartwich; Harikrishna Nakshatri; Kenneth P Nephew; Richard R Behringer; Facundo M Fernández; Chi-Heum Cho; Barbara Vanderhyden; Ronny Drapkin; Robert C Bast; Kathy D Miller; Adam R Karpf; Jaeyeon Kim
Journal:  PLoS Genet       Date:  2020-06-04       Impact factor: 5.917

6.  A dog oviduct-on-a-chip model of serous tubal intraepithelial carcinoma.

Authors:  Marcia de Almeida Monteiro Melo Ferraz; Jennifer Beth Nagashima; Bastien Venzac; Séverine Le Gac; Nucharin Songsasen
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

7.  Evaluating the transcriptional fidelity of cancer models.

Authors:  Da Peng; Rachel Gleyzer; Wen-Hsin Tai; Pavithra Kumar; Qin Bian; Bradley Isaacs; Edroaldo Lummertz da Rocha; Stephanie Cai; Kathleen DiNapoli; Franklin W Huang; Patrick Cahan
Journal:  Genome Med       Date:  2021-04-29       Impact factor: 11.117

8.  Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.

Authors:  Sonia Iyer; Shuang Zhang; Simge Yucel; Heiko Horn; Sean G Smith; Ferenc Reinhardt; Esmee Hoefsmit; Bimarzhan Assatova; Julia Casado; Marie-Charlotte Meinsohn; M Inmaculada Barrasa; George W Bell; Fernando Pérez-Villatoro; Kaisa Huhtinen; Johanna Hynninen; Jaana Oikkonen; Pamoda M Galhenage; Shailja Pathania; Paula T Hammond; Benjamin G Neel; Anniina Farkkila; David Pépin; Robert A Weinberg
Journal:  Cancer Discov       Date:  2020-11-06       Impact factor: 39.397

Review 9.  Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.

Authors:  Monika Kressin; Daniela Fietz; Sven Becker; Klaus Strebhardt
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

10.  Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment.

Authors:  Eleni Maniati; Chiara Berlato; Ganga Gopinathan; Owen Heath; Panoraia Kotantaki; Anissa Lakhani; Jacqueline McDermott; Colin Pegrum; Robin M Delaine-Smith; Oliver M T Pearce; Priyanka Hirani; Joash D Joy; Ludmila Szabova; Ruth Perets; Owen J Sansom; Ronny Drapkin; Peter Bailey; Frances R Balkwill
Journal:  Cell Rep       Date:  2020-01-14       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.